title: Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7).
abstract: Angiotensin peptides have been demonstrated to modulate cellular proliferation, angiogenesis, and dermal repair. In this report, the effects of an analogue of the active angiotensin peptide angiotensin(1-7), namely norLeu3-angiotensin(1-7) (NorLeu3-A(1-7)), on the healing of epithelial wounds are presented. Three models were used to evaluate the normal (rats) and delayed (diabetic mice) healing responses of full-thickness excision wounds and the healing responses of full-thickness incision wounds (rats). NorLeu3-A(1-7) was superior to the naturally occurring angiotensin peptide angiotensin(1-7) and to Regranex (Ortho McNeil, Somerville, N.J.) (a formulation of recombinant platelet-derived growth factor used clinically for the treatment of diabetic ulcers) in accelerating tissue repair. By day 9 (normal rats) and day 11 (diabetic mice), the differences in the rates of closure of full-thickness excision wounds between NorLeu3-A(1-7) and Regranex were statistically significant (n = 5 per group). Full healing was observed for 60 percent of the diabetic mice treated topically with NorLeu3-A(1-7) by day 18 after injury, at which time full healing of wounds on placebo-treated or Regranex-treated diabetic mice was not observed. In the rat incision model, accelerated healing and reduced gross appearance of scarification were observed. Administration of NorLeu3-A(1-7) reduced fibrosis and scarring in the healing wounds. This action was more pronounced with longer administration of the peptide after injury. In fact, if systemic administration of the peptide (NorLeu3-A(1-7)) was continued during the remodeling phase, then the formation of new adnexal structures at the center of full-thickness excision wounds was observed, with an increase in the appearance of small immature hair follicles at the sites of the excision wounds. The action of this peptide was blocked by the AT receptor antagonist d-Ala7-angiotensin(1-7), which suggests that this receptor is involved in the healing responses to exogenous NorLeu3-A(1-7). These data suggest that this novel angiotensin peptide has the potential to be of benefit in accelerating wound repair and reducing scar formation.
authors.affiliation: Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, 1321 N. Mission Road, Los Angeles, CA 90033, USA. kridgers@hsc.usc.edu
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Rodgers
authors.forename: Theresa
authors.initials: T
authors.lastname: Espinoza
authors.forename: Juan
authors.initials: J
authors.lastname: Felix
authors.forename: Norma
authors.initials: N
authors.lastname: Roda
authors.forename: Sonia
authors.initials: S
authors.lastname: Maldonado
authors.forename: Gere
authors.initials: G
authors.lastname: diZerega
mesh_terms: D000803:Angiotensin I; D000804:Angiotensin II / Q000627:therapeutic use*; D000818:Animals; D002921:Cicatrix / Q000473:pathology* / Q000517:prevention & control*; D005260:Female; D051379:Mice; D016688:Mice, Inbred NOD; D010446:Peptide Fragments / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D010446:Peptide Fragments; C473306:norLeu3-A(1-7); D000804:Angiotensin II; D000803:Angiotensin I; C118790:angiotensin I (1-7)